DXB AU000000DXB7

Delayed Australian Stock Exchange - 05/19 12:41:24 am EDT
0.1400	AUD		0.00%

05/08	Dimerix Secures US FDA Approval for Phase 3 Kidney Trial; Shares Rise 4%	MT
05/08	Dimerix Limited Announces Approval of Action3 Phase 3 Clinical Trial of DMX-200 in FSGS	CI
04/26	DIMERIX : Quarterly Appendix 4C and Activities Report	PU

Dimerix Doses First Patients in Phase 3 Study of COVID-19 Respiratory Complications Drug; Shares Rise 6%

01/10/2022 | 08:20pm EDT

All news about DIMERIX LIMITED

05/08	Dimerix Secures US FDA Approval for Phase 3 Kidney Trial; Shares Rise 4%	MT
05/08	Dimerix Limited Announces Approval of Action3 Phase 3 Clinical Trial of DMX-200 in FSGS	CI
04/26	DIMERIX : Quarterly Appendix 4C and Activities Report	PU
03/28	Dimerix Receives $3 Million Tax Rebate; Shares Rise 3%	MT
02/28	DIMERIX : Investor Call and Presentation	PU
02/27	Dimerix Limited Announces DSMB Change to REMAP-CAP COVID-19 Study	CI
02/23	DIMERIX : Half-Year Financial Report & Appendix 4D - 31 December 2021	PU
02/23	Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2021	CI
02/06	Dimerix Names New Chief Medical Officer	MT
02/06	Dimerix Limited Appoints Dr. Ash Soman as Chief Medical Officer	CI

Financials

Chart DIMERIX LIMITED

Duration : Period :

Technical analysis trends DIMERIX LIMITED

	Short Term	Mid-Term	Long Term
Trends	Neutral	Bearish	Bearish

Income Statement Evolution

More Financials

Managers and Directors

Nina Webster	Chief Executive Officer, MD & Director
Hamish George	Chief Financial Officer & Secretary
James Howard Williams	Non-Executive Chairman
David Packham	Chief Medical Officer
Robert Shepherd	Director-Research & Development

Sector and Competitors

		1st jan.	Capi. (M$)
	DIMERIX LIMITED	-42.86%	31

DIMERIX LIMITED